A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
出版年份 2018 全文链接
标题
A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
作者
关键词
-
出版物
Therapeutic Advances in Endocrinology and Metabolism
Volume 9, Issue 3, Pages 69-79
出版商
SAGE Publications
发表日期
2018-01-19
DOI
10.1177/2042018817752315
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
- (2017) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- American Diabetes Association Standards of Medical Care in Diabetes 2017
- (2017) Payal H. Marathe et al. Journal of Diabetes
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
- (2016) Julio Rosenstock et al. DIABETES CARE
- Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
- (2016) Vanita R. Aroda et al. DIABETES CARE
- The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell–Centric Classification Schema
- (2016) Stanley S. Schwartz et al. DIABETES CARE
- Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
- (2016) Kasia J. Lipska et al. DIABETES CARE
- Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin
- (2016) K. Khunti et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial
- (2016) H. W. Rodbard et al. DIABETIC MEDICINE
- Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes
- (2016) Ildiko Lingvay et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
- (2016) Sultan Linjawi et al. Diabetes Therapy
- The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial
- (2016) Sultan Linjawi et al. Diabetes Therapy
- Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
- (2015) M. A. Abdul-Ghani et al. DIABETES OBESITY & METABOLISM
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
- (2014) Hanne Haahr et al. CLINICAL PHARMACOKINETICS
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
- (2013) R. A. DeFronzo et al. DIABETES CARE
- The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
- (2013) S. Stark Casagrande et al. DIABETES CARE
- Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people
- (2013) K. Khunti et al. DIABETES CARE
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes: A randomized, controlled trial
- (2011) T. Heise et al. DIABETES CARE
- Correlates of Insulin Injection Omission
- (2010) M. Peyrot et al. DIABETES CARE
- Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
- (2009) Joshua J Neumiller et al. ANNALS OF PHARMACOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started